Marta Milà-Alomà is a postdoctoral neuroscientist specializing in Alzheimer’s disease (AD), with a research focus on its pathogenesis and early detection through multimodal biomarkers. She is currently a postdoctoral fellow at the Northern California Institute for Research and Education (NCIRE) and the University of California, San Francisco (UCSF), where her work centers on investigating novel plasma biomarkers for the early diagnosis of AD. Her research is supported by the Alzheimer’s Association Research Fellowship (AARF).
Marta is particularly interested in understanding how sex differences influence AD biomarker levels and their trajectories, reflecting disease heterogeneity. Her ultimate goal is to improve diagnostic precision and inform the design of more effective clinical trials. Her work combines advanced statistical modeling, neuroimaging, and fluid biomarker analysis to gain new insights into AD pathophysiology.
She holds degrees in Human Biology (Universitat Pompeu Fabra, Barcelona), Neuropsychology (Universitat Oberta de Catalunya), and an MSc in Neuroscience (Universitat de Barcelona). She completed her PhD in 2022 at the Barcelonabeta Brain Research Center (BBRC), where she investigated fluid biomarkers in preclinical AD. Her doctoral research led to several first-author publications in high-impact journals including Nature Medicine, JAMA Neurology, and Alzheimer’s & Dementia.